Activity of the histone deacetylase inhibitor FR235222 on Toxoplasma gondii: Inhibition of stage conversion of the parasite cyst form and study of new derivative compounds

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 11, 2010, Pages 4843-4850

  Maubon, Danièle ^a,b   Bougdour, Alexandre ^b   Wong, Yung Sing ^b   Brenier Pinchart, Marie Pierre ^a,b   Curt, Aurélie ^b   Hakimi, Mohamed Ali ^b   Pelloux, Hervé ^a,b  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

^b UNIV GRENOBLE ALPES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPROTOZOAL AGENT; FR 235222; HISTONE DEACETYLASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; BRADYZOITE; CELL LABELING; CELL WALL; CONTROLLED STUDY; CYST (RESTING STAGE); DRUG SYNTHESIS; EX VIVO STUDY; FEMALE; IMMUNOFLUORESCENCE MICROSCOPY; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOXOPLASMA GONDII; TOXOPLASMOSIS; WESTERN BLOTTING;

EID: 78049278807     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00462-10     Document Type: Article

References (36)

1. Araujo, F. G., J. Huskinson-Mark, W. E. Gutteridge, and J. S. Remington. 1992. In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii. Antimicrob. Agents Chemother. 36:326-330.
2. Araujo, F. G., J. Huskinson, and J. S. Remington. 1991. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob. Agents Chemother. 35:293-299.
3. Baatz, H., A. Mirshahi, J. Puchta, H. Gumbel, and L. O. Hattenbach. 2006. Reactivation of Toxoplasma retinochoroiditis under atovaquone therapy in an immunocompetent patient. Ocul. Immunol. Inflamm. 14:185-187.
4. Beck, H. P., D. Blake, M. L. Darde, I. Felger, S. Pedraza-Diaz, J. Regidor-Cerrillo, M. Gomez-Bautista, L. M. Ortega-Mora, L. Putignani, B. Shiels, A. Tait, and W. Weir. 2009. Molecular approaches to diversity of populations of apicomplexan parasites. Int. J. Parasitol. 39:175-189.
5. Boothroyd, J. C. 2009. Toxoplasma gondii: 25 years and 25 major advances for the field. Int. J. Parasitol. 39:935-946.
6. Bougdour, A., D. Maubon, P. Baldacci, P. Ortet, O. Bastien, A. Bouillon, J. C. Barale, H. Pelloux, R. Menard, and M. A. Hakimi. 2009. Drug inhibition of HDAC3 and epigenetic control of differentiation in Apicomplexa parasites. J. Exp. Med. 206:953-966.
7. Bougdour, A., C. F. Sautel, D. Cannella, L. Braun, and M. A. Hakimi. 2008. Toxoplasma gondii gene expression is under the control of regulatory pathways acting through chromatin structure. Parasite 15:206-210.
8. Braun, L., D. Cannella, A. M. Pinheiro, S. Kieffer, H. Belrhali, J. Garin, and M. A. Hakimi. 2009. The small ubiquitin-like modifier (SUMO)-conjugating system of Toxoplasma gondii. Int. J. Parasitol. 39:81-90.
9. Brenier-Pinchart, M. P., V. Morand-Bui, H. Fricker-Hidalgo, V. Equy, R. Marlu, and H. Pelloux. 2007. Adapting a conventional PCR assay for Toxoplasma gondii detection to real-time quantitative PCR including a competitive internal control. Parasite 14:149-154.
10. Chirgwin, K., R. Hafner, C. Leport, J. Remington, J. Andersen, E. M. Bosler, C. Roque, N. Rajicic, V. McAuliffe, P. Morlat, D. T. Jayaweera, J. L. Vilde, and B. J. Luft. 2002. Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039. Clin. Infect. Dis. 34:1243-1250.
11. Cornelissen, A. W., J. P. Overdulve, and J. M. Hoenderboom. 1981. Separation of Isospora (Toxoplasma) gondii cysts and cystozoites from mouse brain tissue by continuous density-gradient centrifugation. Parasitology 83:103-108.
12. Darkin-Rattray, S. J., A. M. Gurnett, R. W. Myers, P. M. Dulski, T. M. Crumley, J. J. Allocco, C. Cannova, P. T. Meinke, S. L. Colletti, M. A. Bednarek, S. B. Singh, M. A. Goetz, A. W. Dombrowski, J. D. Polishook, and D. M. Schmatz. 1996. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl. Acad. Sci. U. S. A. 93:13143-13147.
13. Fricker-Hidalgo, H., C. E. Bulabois, M. P. Brenier-Pinchart, R. Hamidfar, F. Garban, J. P. Brion, J. F. Timsit, J. Y. Cahn, and H. Pelloux. 2009. Diagnosis of toxoplasmosis after allogeneic stem cell transplantation: results of DNA detection and serological techniques. Clin. Infect. Dis. 48:e9-e15.
14. Fung, H. B., and H. L. Kirschenbaum. 1996. Treatment regimens for patients with toxoplasmic encephalitis. Clin. Ther. 18:1037-1056.
15. Gomez-Paloma, L., I. Bruno, E. Cini, S. Khochbin, M. Rodriquez, M. Taddei, S. Terracciano, and K. Sadoul. 2007. Design and synthesis of cyclopeptide analogues of the potent histone deacetylase inhibitor FR235222. ChemMedChem 2:1511-1519.
16. Gross, U., H. Bormuth, C. Gaissmaier, C. Dittrich, V. Krenn, W. Bohne, and D. J. Ferguson. 1995. Monoclonal rat antibodies directed against Toxoplasma gondii suitable for studying tachyzoite-bradyzoite interconversion in vivo. Clin. Diagn. Lab. Immunol. 2:542-548.
17. Hakimi, M. A., and K. W. Deitsch. 2007. Epigenetics in Apicomplexa: control of gene expression during cell cycle progression, differentiation and antigenic variation. Curr. Opin. Microbiol. 10:357-362.
18. Hill, D. E., S. Chirukandoth, and J. P. Dubey. 2005. Biology and epidemiology of Toxoplasma gondii in man and animals. Anim. Health Res. Rev. 6:41-61.
19. Huskinson-Mark, J., F. G. Araujo, and J. S. Remington. 1991. Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii. J. Infect. Dis. 164:170-171.
20. Iyer, L. M., V. Anantharaman, M. Y. Wolf, and L. Aravind. 2008. Comparative genomics of transcription factors and chromatin proteins in parasitic protists and other eukaryotes. Int. J. Parasitol. 38:1-31.
21. Kim, S. K., and J. C. Boothroyd. 2005. Stage-specific expression of surface antigens by Toxoplasma gondii as a mechanism to facilitate parasite persistence. J. Immunol. 174:8038-8048.
22. Lyons, R. E., R. McLeod, and C. W. Roberts. 2002. Toxoplasma gondii tachyzoite-bradyzoite interconversion. Trends Parasitol. 18:198-201.
23. Megged, O., I. Shalit, I. Yaniv, J. Stein, S. Fisher, and I. Levy. 2008. Breakthrough cerebral toxoplasmosis in a patient receiving atovaquone prophylaxis after a hematopoietic stem cell transplantation. Pediatr. Transplant. 12:902-905.
24. Meneceur, P., M. A. Bouldouyre, D. Aubert, I. Villena, J. Menotti, V. Sauvage, J. F. Garin, and F. Derouin. 2008. In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone. Antimicrob. Agents Chemother. 52:1269-1277.
25. Montoya, J. G., and O. Liesenfeld. 2004. Toxoplasmosis. Lancet 363:1965-1976.
26. Mori, H., Y. Urano, F. Abe, S. Furukawa, S. Furukawa, Y. Tsurumi, K. Sakamoto, M. Hashimoto, S. Takase, M. Hino, and T. Fujii. 2003. FR235222, a fungal metabolite, is a novel immunosuppressant that inhibits mammalian histone deacetylase (HDAC). I. Taxonomy, fermentation, isolation and biological activities. J. Antibiot. (Tokyo) 56:72-79.
27. Nwaka, S., and A. Hudson. 2006. Innovative lead discovery strategies for tropical diseases. Nat. Rev. Drug Discov. 5:941-955.
28. Olliaro, P. 2005. Drug resistance hampers our capacity to roll back malaria. Clin. Infect. Dis. 41(Suppl. 4):S247-S257.
29. Petrella, A., C. W. D'Acunto, M. Rodriquez, M. Festa, A. Tosco, I. Bruno, S. Terracciano, M. Taddei, L. G. Paloma, and L. Parente. 2008. Effects of FR235222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukaemia cell lines: role of annexin A1. Eur. J. Cancer 44:740-749.
30. Pfefferkorn, E. R., and L. C. Pfefferkorn. 1977. Specific labeling of intracellular Toxoplasma gondii with uracil. J. Protozool. 24:449-453.
31. Rezai, T., J. E. Bock, M. V. Zhou, C. Kalyanaraman, R. S. Lokey, and M. P. Jacobson. 2006. Conformational flexibility, internal hydrogen bonding, and passive membrane permeability: successful in silico prediction of the relative permeabilities of cyclic peptides. J. Am. Chem. Soc. 128:14073-14080.
32. Saksouk, N., M. M. Bhatti, S. Kieffer, A. T. Smith, K. Musset, J. Garin, W. J. Sullivan, Jr., M. F. Cesbron-Delauw, and M. A. Hakimi. 2005. Histone-modifying complexes regulate gene expression pertinent to the differentiation of the protozoan parasite Toxoplasma gondii. Mol. Cell. Biol. 25:10301-10314.
33. Shahbazian, M. D., and M. Grunstein. 2007. Functions of site-specific histone acetylation and deacetylation. Annu. Rev. Biochem. 76:75-100.
34. Sullivan, W. J., Jr., and M. A. Hakimi. 2006. Histone mediated gene activation in Toxoplasma gondii. Mol. Biochem. Parasitol. 148:109-116.
35. Tardieux, I., and R. Menard. 2008. Migration of Apicomplexa across biological barriers: the Toxoplasma and Plasmodium rides. Traffic 9:627-635. (Pubitemid 351494295)
36. Van, T. T., S.-K. Kim, M. Camps, J. C. Boothroyd, and L. J. Knoll. 2007. The BSR4 protein is up-regulated in Toxoplasma gondii bradyzoites, however the dominant surface antigen recognised by the P36 monoclonal antibody is SRS9. Int. J. Parasitol. 37:877.